| Place of Origin: | China |
|---|---|
| Brand Name: | HNB |
| Certification: | ISO |
| Model Number: | Pimobendan |
| Minimum Order Quantity: | 1KG |
| Price: | Negotiable |
| Packaging Details: | Aluminum foil bag |
| Delivery Time: | Usually7-10days |
| Payment Terms: | L/C, D/A, D/P, T/T, Western Union, MoneyGram |
| Supply Ability: | 5000kg/Month |
| CAS: | 74150-27-9 | Mf: | C19H18N4O2 |
|---|---|---|---|
| MW: | 334.372 | Specification: | ≥98% |
| Einecs No.: | N/A | Appearance: | White Crystalline Powder |
CAS 74150-27-9 PDE inhibitor Cardiotonic Drug Pimobendan Powder
|
Product Name |
Pimobendan |
|
Function |
APIs |
|
Specification |
99%Tech |
|
Chemical Name |
(RS)-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-4,5-dihydropyridazin-3(2H)-one |
|
CAS No. |
|
|
Empirical Formula |
C19H18N4O2 |
|
Toxicology |
Details of toxic effects not reported other than lethal dose value |
|
Applications |
Pimobendam is a chemical used to treat mild, moderate, or severe congestive heart failure caused by atrioventricular insufficiency or cardiac hypertrophy in dogs. |
|
Package |
1kg/bag,25kg/drum |
The Introductction of Pimobendan:
Pimobendan is a selective inhibitor of PDE3 with IC50 of 0.32 μM.Target: PDE3Pimobendan exhibits selective inhibition of PDE III isolated from guinea pig cardiac muscle with IC50 of 0.32 uM compared to the inhibition of PDE I and PDE II (IC50s >30 μM). In human atrial cells, 100 μM pimobendan significantly increases the L-type calcium current (ICa(L)) (evoked by depolarization to +10 mV from a holding potential of -40 mV) by 250.4% with the half-maximal stimulation (EC50) of 1.13 μM. In rabbit atrial cells, Pimobendan increases ICa(L) at +10 mV by 67.4.%, which is significantly lower than that obtained in human atrial cells Pimobendan shows a beneficial effect on survival in the murine model of EMC virus-induced myocarditis.
The Application & Function of Pimobendan:
Pimobendam is a chemical used to treat mild, moderate, or severe congestive heart failure caused by atrioventricular insufficiency or cardiac hypertrophy in dogs.
Application:
Pimobendan is a selective inhibitor of PDE3 with IC50 of 0.32 μM.Target: PDE3Pimobendan exhibits selective inhibition of PDE III isolated from guinea pig cardiac muscle with IC50 of 0.32 uM compared to the inhibition of PDE I and PDE II (IC50s >30 μM). In human atrial cells, 100 μM pimobendan significantly increases the L-type calcium current (ICa(L)) (evoked by depolarization to +10 mV from a holding potential of -40 mV) by 250.4% with the half-maximal stimulation (EC50) of 1.13 μM. In rabbit atrial cells, Pimobendan increases ICa(L) at +10 mV by 67.4.%, which is significantly lower than that obtained in human atrial cells Pimobendan shows a beneficial effect on survival in the murine model of EMC virus-induced myocarditis.
The COA of Pimobendan
|
